65th ASH Annual Meeting & Exposition: 703. Cellular Immunotherapies: Basic and Translational: Innovative T Cell Therapies for Unexplored Frontiers

Symposia: Cellular Immunotherapies: Basic and Translational Oral and Poster Abstracts
Oral

Research, Fundamental Science, Biological therapies, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Gene Therapy, Therapies, Immunotherapy

Room 6B (San Diego Convention Center)

Moderators:

M. Eric Kohler, MD, PhD, University of Colorado School of Medicine and Arnab Ghosh, Arnab Ghosh

Disclosures:

Ghosh: GLG: Consultancy; Group H: Consultancy; Doximity: Current equity holder in publicly-traded company.

2:45 PM

883

Dual Split-Signaling TIM3+CLEC12a Targeting CAR T-Cells with Optimized Signaling As a Safe Potential Therapy for Acute Myeloid Leukemia

Jort J Van Der Schans, MSc^1,2^*, Paresh Vishwasrao, MSc^1,2^*, Noortje Van Gils, PhD^1,2^*, Mashhour Hosny, Msc^1,2^*, Ziyu Wang^1,2^*, Jennemiek Van Arkel^1,2^*, Sonja Zweegman, MD, PhD^1,2, Maria Themeli, MD, PhD^1,2^*, Gert Ossenkoppele, MD, PhD^1,2, Niels W.C.J. van de Donk^1,2^*, Arjan A. Van de Loosdrecht, MD, PhD^1,2, Linda Smit, PhD^1,2^* and Tuna Mutis, MD PhD^1,2^*

¹Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
²Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands

3:00 PM

884

Naturally Occurring Mutations in Human T Cell Lymphomas Enhance Engineered T Cell Therapies

Julie Garcia¹^*, Jay Daniels²^*, Yujin Lee³^*, Iowis Zhu¹^*, Kathleen Cheng³^*, Qing Liu³^*, Daniel Goodman¹^*, Cassandra Burnett¹^*, Calvin Law³^*, Chloe Thienpoint¹^*, Josef Alavi¹^*, Camillia Azimi¹^*, Garrett Montgomery¹^*, Kole Roybal¹^* and Jaehyuk Choi, MD, PhD⁴

¹UCSF, San Francisco, CA
²Northwestern University, Seattle, WA
³Northwestern University, Chicago, IL
⁴Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL

3:15 PM

885

Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms

Mathew G. Angelos, MD, PhD^1,2, Ruchi P. Patel, MS¹, Yi-Hao Chiang, MD³^*, Wei Xie, MD³^*, Raymone Pajarillo, MS¹^*, Carolyn E. Shaw, MS³^*, Ekta Singh, BS³^*, Jason Xu, PhD⁴, Avery D. Posey, PhD³^*, Alain Rook, MD⁵^*, Antonia Rotolo, MD, PhD³^*, Vinodh Pillai, MD, PhD⁶^*, Stefano A. Pileri, MD, PhD⁷, David T. Teachey, MD⁴ and Marco Ruella, MD^1,8

¹Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
²Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
³Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
⁴Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
⁵Division of Dermatology, University of Pennsylvania, Philadelphia, PA
⁶Division of Hematopathology, Children's Hospital of Philadelphia, Philadelphia, PA
⁷Division of Hematopathology, Istituto Europeo di Oncologia, Milano, Italy
⁸Lymphoma Program, University of Pennsylvania, Philadelphia, PA

3:30 PM

886

Human ILC1s Target Leukemia Stem Cells and Control Development of AML

Zhenlong Li, PhD¹^*, Hejun Tang¹^*, Victoria Chen²^*, Rui Ma¹^*, Jianying Zhang, PhD¹^*, Guido Marcucci, MD^3,4, Jianhua Yu, PhD⁵ and Michael A Caligiuri, MD^6,7,8,9

¹Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, City of Hope National Medical Center, Duarte, CA
²City of hope, Duarte, CA
³Hematology/HCT, City of Hope National Medical Center, Duarte, CA
⁴Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA
⁵Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
⁶City of Hope Comprehensive Cancer Center and Beckman Research Institute, Los Angeles, CA
⁷Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA
⁸Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Los Angeles, CA
⁹Department of Immuno-Oncology, City of Hope Beckman Research Institute, Los Angeles, CA

3:45 PM

887

A Rare Cell State Underpins Diverse Mechanisms of Adaptive Resistance to CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

James A Kuzich, MBBS, FRACP, FRCPA^1,2,3, Laure Talarmain, PhD^1,2^*, Dane Vassiliadis, PhD^1,2^*, Andrew A Guirguis, MD, PhD^1,2,3, Jack D Chan, PhD^1,2^*, Paul A Beavis, PhD^1,2^*, Phillip K Darcy, PhD^1,2^*, Ashley P Ng, PhD, MBBS, FRACP, FRCPA^3,4^* and Mark A. Dawson, MBBS, PhD, FRACP, FRCPA^2,5

¹Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
²Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
³Clinical Haematology, Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, VIC, Australia
⁴Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
⁵Peter Maccallum Cancer Centre, Melbourne, VIC, Australia

4:00 PM

888

Adoptive Transfer of T Cells Genetically Engineered to Express T-Cell Receptors Targeting Neoantigens Arising from p53 and Ras Hotspot Mutations in Hematologic Malignancies

Kathryn M Cappell, MD, PhD, Sanghyun P Kim, PhD^*, Noam Levin, PhD^*, Norris Lam, BS^*, Christina Amatya, PhD^*, Lauren C Cutmore, PhD^*, Rachel Beyer, PhD^*, Steven A Rosenberg, MD, PhD^* and James N Kochenderfer, M.D.^*

Surgery Branch, National Cancer Institute, Bethesda, MD

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703A.O3.6 703. Cellular Immunotherapies: Basic and Translational: Innovative T Cell Therapies for Unexplored Frontiers